• Kairos Pharma released interim Phase 1 safety data for ENV-105 with AstraZeneca’s Tagrisso in advanced EGFR-mutated NSCLC.
• No Grade 3 or higher adverse events were reported in 13 treated patients; results support continued dosing toward an early efficacy readout.
• Program targets acquired resistance to osimertinib in an EGFR-NSCLC market estimated at about $10 billion; Tagrisso generates about $6 billion annual sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260715232897) on July 15, 2026, and is solely responsible for the information contained therein.